Download PDF
Thromb Haemost 1995; 74(01): 377-381
DOI: 10.1055/s-0038-1642706
Symposium
Platelet Vessel Wall Interaction as a Target of Antithrombotic Terapy
Schattauer GmbH Stuttgart

Clinical Trials of Primary and Secondary Prevention of Thrombosis and Restenosis

J Vermylen
Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389
    PubMedGoogle Scholar
  • 2 MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994 344. 633-638
    PubMedGoogle Scholar
  • 3 Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis andthrombosis. FASEB J 1994; 8: 1279-1284
    CrossrefPubMedGoogle Scholar
  • 4 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC, Vitamin E. consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-1456
    CrossrefPubMedGoogle Scholar
  • 5 Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC, Vitamin E. consumption and the risk of coronary heart disease in women. N Engl J Med 1993; 328: 1444-1449
    CrossrefPubMedGoogle Scholar
  • 6 Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Emster VL. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037
    CrossrefPubMedGoogle Scholar
  • 7 Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women Arch Intern Med 1990; 150: 2557-2562
    CrossrefPubMedGoogle Scholar
  • 8 Keaney Jr JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17 b-estrodiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994; 89: 2251-2259
    CrossrefPubMedGoogle Scholar
  • 9 Heras M, Chesebro JH, Webster MW, Mruk JJ, Grill DE, Penny WJ, Bowie EJ, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury inthe pig. The in vivo role of thrombin inplatelet-mediated thrombosis Circulation 1990; 82: 1476-1484
    CrossrefPubMedGoogle Scholar
  • 10 Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991; 84: 232-243
    CrossrefPubMedGoogle Scholar
  • 11 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. 2d. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101
    CrossrefPubMedGoogle Scholar
  • 12 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536
    CrossrefPubMedGoogle Scholar
  • 13 Antman EM. for the TIMI-9A Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630
    CrossrefPubMedGoogle Scholar
  • 14 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes.. Circulation. 1994; 90: 1631-1637
    PubMedGoogle Scholar
  • 15 Dunwiddie C, Thom berry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E, Antistasi n. a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site J Biol Chem 1989; 264: 16694-16699
    PubMedGoogle Scholar
  • 16 Vlasuk CP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemostas 1993; 70: 212-216
    PubMedGoogle Scholar
  • 17 Coughlin SR, Vu TK, Hung DT, Wheaton TI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest 1992; 89: 351-355
    CrossrefPubMedGoogle Scholar
  • 18 Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-551
    CrossrefPubMedGoogle Scholar
  • 19 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 20 Verstraete M, Vermylen J, Roberts HR. (eds). The challenge of clinical trials in thrombosis. K Schattauer Verlag; Stuttgart: 1979
    Google Scholar
  • 21 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS- 2. Lancet. 1988; 2: 349-360
    PubMedGoogle Scholar
  • 22 Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Bri Med J Clin Res 1988; 296: 320-331
    PubMed
  • 23 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.. BMJ 1994; 308: 81-106
    CrossrefPubMed
  • 24 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy.. BMJ 1994; 308: 159-68
    CrossrefPubMed
  • 25 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Ill: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.. BMJ 1994; 308: 235-46
    CrossrefPubMed
  • 26 Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. et al. Randomized trial of prophylactic daily aspirin in British male doctors. BrMed J Clin Res Ed 1988; 296: 3136
    PubMedGoogle Scholar
  • 27 Steering Committee of the Physicians ’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129-135
    CrossrefPubMedGoogle Scholar
  • 28 Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliot G, Panju A, Brant R. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376
    CrossrefPubMedGoogle Scholar
  • 29 Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basil F, Klimek J, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-529
    CrossrefPubMedGoogle Scholar
  • 30 Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, Fuster V. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group Am J Cardiol 1994; 74: 657-661
    CrossrefPubMedGoogle Scholar
  • 31 Meade TW. Low-intensity oral anticoagulation. In: Thrombosis and its management. Poller L, Thomson JM. eds. Churchill Livingstone; Edinburgh: 1993: 84-97
    Google Scholar
  • 32 Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemostas 1992; 68: 1-6
    PubMedGoogle Scholar
  • 33 Clagett GP, Graor RA, Salzman EW. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1992; 102 Suppl (Suppl. 04) 516S-528S
    CrossrefPubMedGoogle Scholar
  • 34 Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molonu BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 1989; 321: 501-507
    CrossrefPubMedGoogle Scholar
  • 35 Herbert JM, Frehel D, Bemat A, Badorc A, Savi P, Delebassee D, et al. Gopidogre l. a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198
    CrossrefPubMedGoogle Scholar
  • 36 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 78: 3073-3076
    PubMedGoogle Scholar
  • 37 Vermylen J, Deckmyn H. Thromboxane synthase inhibitors and receptor antagonists. Cardiovasc Dmgs Ther 1992; 6: 29-33
    PubMedGoogle Scholar
  • 38 De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen PA. R68070thromboxane A2 synthetase inhibition and thromboxane A2/ prostaglandin endoperoxide receptor blockade combined in one molecule. I: biochemical profile in vitro Thromb Haemostas 1989; 61: 35-12
    PubMedGoogle Scholar
  • 39 Hoet B, Amout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermylen J, Ridogre l. A combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma b-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemostas 1990; 64: 8790
    PubMedGoogle Scholar
  • 40 The RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane Aj/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT).. Circulation. 1994; 89: 588-595
    PubMedGoogle Scholar
  • 41 Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1988; 9: 117-156
    PubMedGoogle Scholar
  • 42 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein Ilb-IIIa (integrin allbb3) mediated by fibrinogen and glycoprotein lb - von Willebrand factor J Biol Chem 1992; 267: 11300-11306
    PubMedGoogle Scholar
  • 43 Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Amout J. MK-383 (L700,462), a selective nonpeptide platelet glycoprotein Ilb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-1517
    CrossrefPubMedGoogle Scholar
  • 44 Collen D, Lu HR, Stassen JM, Yreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemostas 1994; 71: 95-102
    PubMedGoogle Scholar
  • 45 Kereiakes D, Kleiman N, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver WD, McKee D, Sax FL. A dosing study in high-risk PTCA of MK-383, a platelet Ilb-IIIa antagonist. Circulation 1994; 90: 1-21 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 46 Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan LB, Deschenes N, Fitzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994; 90: 1-231 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 47 Theroux P, Kouz S, Knudtson ML, Kells C, Nasmith J, Roy L, Ave SD, Steiner B, Xiao Z, Rapold HJ. A randomized double-bind controlled trial with the non-peptide platelet GPIIb/IIIa antagonist RO 44-9883in unstable angina. Circulation 1994; 90: 1-232 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 48 Harrington RA, Schulman SP, Kleiman NS, Lincoff AM, Goldschmidt-Clermont PJ, Joseph D, Sigmon KN, Parker J, Marchant K, Kitt MM. Profound,sustained and reversible platelet inhibition following administration of a glycoprotein Ilb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 1994; 90: 1-232 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 49 Ohman EM, Kleiman NS, Talley JD, Gacioch G, Navetta FI, Carney RJ, Worley S, Anderson HV, Cohen M, Kereiakes D, Joseph D, Sigmon KN, Topol EJ. for the IMPACT-AMI study Group. Simultaneous platelet glycoprotein Ilb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 1994; 90: 1-564 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 50 Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease Drugs 1994; 48: 58398
    PubMedGoogle Scholar
  • 51 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty.. N Engl J Med 1994; 330: 956-961
    CrossrefPubMed
  • 52 Topol EJ, Califf RM, Weisman HF, Eliss SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Wester M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
    CrossrefPubMedGoogle Scholar
  • 53 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
    CrossrefPubMedGoogle Scholar
  • 54 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avb3 integrin with a small peptide antagonist G-pen GRGDSPCA. J Vase Surg 1994; 19: 125-134
    CrossrefPubMedGoogle Scholar